Fisetin Supplementation for Healthy Aging

Summary

There is growing interest among the general population in preventive health interventions that can help mitigate age-related decline, reduce the risk of chronic diseases, and promote healthy aging. The use of nutritional supplements has been increasing and is especially high in older adults and healthier individuals. In response to this demand, a growing number of nutritional supplements are being advertised for their "anti-aging" properties, claiming to target molecular and cellular "hallmarks of aging", such as chronic inflammation, oxidative stress, and cellular senescence. However, the overwhelming majority of these claims stem from preclinical studies in animal models (e.g., C. elegans, mice), and there is extremely limited evidence for beneficial effects, effective doses, or safety profiles of these supplements in humans. Moreover, the lack of strict regulations in the nutritional supplement industry leads to wide differences in the quality and in the actual content of active substances between supplements, which could impact both their efficacy and safety.

The investigators will conduct a clinical trial in healthy volunteers, who will receive supplementation with fisetin (100 mg) or placebo daily for 7 weeks. Participants will be examined at regular intervals during the study period. The investigators will then investigate whether fisetin supplementation is safe and evaluate its effect on measures of chronic inflammation, cellular senescence, aging, and general health.

Conditions

• Healthy

Interventions

DIETARY_SUPPLEMENT

Fisetin

One capsule (100 mg) daily

DIETARY_SUPPLEMENT

Placebo

One capsule daily

Sponsors & Collaborators

• Ove Andersen

  lead OTHER

Principal Investigators

• Juliette Tavenier · Copenhagen University Hospital, Amager and Hvidovre

• Line Jee Hartmann Rasmussen · Copenhagen University Hospital, Amager and Hvidovre

• Morten B Houlind · Copenhagen University Hospital, Amager and Hvidovre

• Magnus Berglind · Copenhagen University Hospital, Amager and Hvidovre

• Line Fleischer Hach · Copenhagen University Hospital, Amager and Hvidovre

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

50 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-09-24

Primary Completion

2026-10-31

Completion

2026-10-31

Countries

• Denmark

Study Locations